Comparative Pharmacology
Head-to-head clinical analysis: MUCOMYST W ISOPROTERENOL versus MUCOSIL 10.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MUCOMYST W ISOPROTERENOL versus MUCOSIL 10.
MUCOMYST W/ ISOPROTERENOL vs MUCOSIL-10
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Acetylcysteine reduces mucous viscosity by cleaving disulfide bonds in mucoproteins, enhancing clearance of respiratory secretions. Isoproterenol is a non-selective beta-adrenergic agonist that stimulates beta-1 and beta-2 receptors, causing bronchodilation and increased mucociliary clearance.
MUCOSIL-10 is a mucolytic agent containing N-acetylcysteine. It reduces mucus viscosity by cleaving disulfide bonds in mucoproteins via free sulfhydryl groups, thereby facilitating expectoration. It also exhibits antioxidant properties by replenishing glutathione stores and neutralizing reactive oxygen species.
Acetylcysteine 10-20% solution 3-5 mL via nebulization with isoproterenol 0.5 mL (0.5 mg) q6-8h; isoproterenol dose adjusted to heart rate not exceeding 120/min.
10 mg orally once daily
None Documented
None Documented
Acetylcysteine: terminal half-life is approximately 5.6 hours in adults (range 3-8 hours); increased in patients with hepatic impairment. Isoproterenol: half-life is approximately 2.5-5 minutes due to rapid hepatic and tissue metabolism.
Terminal elimination half-life is approximately 3-4 hours in adults with normal renal function; may be prolonged to 6-8 hours in patients with moderate renal impairment (CrCl <50 mL/min).
Acetylcysteine and isoproterenol are both extensively metabolized. Acetylcysteine is metabolized in the liver to cysteine and other metabolites; renal excretion of inorganic sulfate and unchanged drug accounts for less than 30% of the dose. Isoproterenol is rapidly metabolized by COMT and other pathways; less than 2% is excreted unchanged in urine.
Primarily renal elimination with 60-70% of the dose excreted unchanged in urine; biliary/fecal excretion accounts for 10-15% as metabolites, with the remainder via other pathways.
Category C
Category C
Mucolytic/Bronchodilator Combination
Mucolytic